Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
28 03 2023
Historique:
accepted: 06 04 2022
received: 29 11 2021
pubmed: 22 4 2022
medline: 22 3 2023
entrez: 21 4 2022
Statut: ppublish

Résumé

We compared the efficacy and safety of eltrombopag (ELTR) combined with immunosuppressive therapy (IST) and IST alone in treatment-naïve children with severe (SAA) and very severe (vSAA) aplastic anemia. Ninety-eight pediatric patients were randomized to receive horse antithymocyte globulin (hATG) and cyclosporin A (CsA) with (n = 49) or without (n = 49) ELTR. The primary endpoint was the overall response rate (ORR) at 4 months. After 4 months, nonresponders were crossed over to the alternative group. In all patients, the ORR in ELTR + IST and IST groups was similar (65% vs 53%; P = .218); however, the complete response (CR) rate was significantly higher in the ELTR + IST group (31% vs 12%; P = .027). In severity subgroups, the ORR was 89% vs 57% (P = .028) in favor of IST + ELTR in SAA, but it did not differ in patients with vSAA (52% vs 50%; P = .902). At 6 months after the crossover, 61% of initial ELTR(-) patients achieved a response compared with 17% of initial ELTR(+) patients (P = .016). No significant difference in ELTR + IST and IST groups was observed in the 3-year overall survival (OS) (89% vs 91%; P = .673) or the 3-year event-free survival (EFS) (53% vs 41%; P = .326). There was no unexpected toxicity related to ELTR. Adding ELTR to standard IST was well tolerated and increased the CR rate. The greatest benefit from ELTR combined with IST was observed in patients with SAA but not in those with vSAA. The second course of IST resulted in a high ORR in initial ELTR(-) patients who added ELTR and had limited efficacy among patients who received ELTR upfront. This trial was registered at Clinicaltrials.gov as #NCT03413306.

Identifiants

pubmed: 35446936
pii: 485028
doi: 10.1182/bloodadvances.2021006716
pmc: PMC10027512
doi:

Substances chimiques

Immunosuppressive Agents 0
eltrombopag S56D65XJ9G

Banques de données

ClinicalTrials.gov
['NCT03413306']

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

953-962

Informations de copyright

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

N Engl J Med. 2022 Jan 6;386(1):11-23
pubmed: 34986284
Exp Hematol. 2006 Jul;34(7):826-31
pubmed: 16797409
Blood. 2014 Mar 20;123(12):1818-25
pubmed: 24345753
Haematologica. 2014 Apr;99(4):664-71
pubmed: 24213150
Haematologica. 2009 May;94(5):712-9
pubmed: 19336743
Blood. 2011 Apr 28;117(17):4434-41
pubmed: 21233311
Blood. 2012 Jun 7;119(23):5391-6
pubmed: 22544699
Br J Haematol. 2015 May;169(4):565-73
pubmed: 25683884
Am J Hematol. 2014 Jun;89(6):571-4
pubmed: 24971433
N Engl J Med. 2012 Jul 5;367(1):11-9
pubmed: 22762314
Cancer. 2018 Nov 1;124(21):4192-4201
pubmed: 30307606
J Pediatr. 2008 Dec;153(6):814-9
pubmed: 18672253
N Engl J Med. 2011 Aug 4;365(5):430-8
pubmed: 21812672
Clin Pharmacol Ther. 2018 Dec;104(6):1199-1207
pubmed: 29536526
Hematology Am Soc Hematol Educ Program. 2013;2013:76-81
pubmed: 24319166
Blood. 2017 Mar 16;129(11):1428-1436
pubmed: 28096088
Haematologica. 2014 Dec;99(12):1784-91
pubmed: 25193958
Pediatr Clin North Am. 2013 Dec;60(6):1311-36
pubmed: 24237973
Osteoporos Int. 2021 Jun;32(6):1227-1231
pubmed: 33244623
Br J Haematol. 2014 Feb;164(4):546-54
pubmed: 24261566
Haematologica. 2015 Dec;100(12):1546-52
pubmed: 26315930
Br J Haematol. 2021 Feb;192(3):605-614
pubmed: 33410523
Cytometry B Clin Cytom. 2018 Jan;94(1):49-66
pubmed: 29236350
Stem Cells. 2009 Feb;27(2):424-30
pubmed: 19038790
N Engl J Med. 2017 Apr 20;376(16):1540-1550
pubmed: 28423296
Lancet. 1988 Feb 6;1(8580):303-4
pubmed: 2893118
Int J Lab Hematol. 2020 Oct;42(5):589-593
pubmed: 32449605
Br J Haematol. 2015 Nov;171(4):585-94
pubmed: 26223288
Br J Haematol. 2008 Jan;140(2):197-205
pubmed: 18173756
Intern Med. 2021 Apr 15;60(8):1159-1168
pubmed: 33229810

Auteurs

Olga Goronkova (O)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Galina Novichkova (G)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Tatiana Salimova (T)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Irina Kalinina (I)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Dina Baidildina (D)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Ulyana Petrova (U)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Kristina Antonova (K)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Maria Sadovskaya (M)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Elena Suntsova (E)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Dmitry Evseev (D)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Victor Matveev (V)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Dmitry Venyov (D)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Lili Khachatryan (L)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Dmitry Litvinov (D)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Alexey Pshonkin (A)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Galina Ovsyannikova (G)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Natalia Kotskaya (N)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Darina Gobadze (D)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Yulia Olshanskaya (Y)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Alexander Popov (A)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Elena Raykina (E)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Olga Mironenko (O)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Kirill Voronin (K)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Bazarma Purbueva (B)

Pirogov Russian Clinical Children's Hospital, Moscow, Russia.

Elmira Boichenko (E)

St. Petersburg Children's City Hospital No 1, St. Petersburg, Russia.

Yulia Dinikina (Y)

Almazov National Medical Research Center, St. Petersburg, Russia.

Evgeniya Guseynova (E)

Krasnoyarsk Regional Clinical Hospital, Krasnoyarsk, Russia.

Dmitry Sherstnev (D)

Shustov University Clinical Hospital No 3 of Razumovsky Saratov State Medical University, Saratov, Russia.

Elena Kalinina (E)

Samara Regional Clinical Children's Hospital, Samara, Russia.

Sergey Mezentsev (S)

Perm Regional Clinical Hospital, Perm, Russia.

Olga Streneva (O)

Ekaterinburg Regional Clinical Children's Hospital, Ekaterinburg, Russia.

Natalia Yudina (N)

Voronezh Regional Clinical Children's Hospital No 1, Voronezh, Russia.

Olga Plaksina (O)

Regional Clinical Children's Hospital, Nizhniy Novgorod, Russia.

Elena Erega (E)

Piotrovich Regional Clinical Children's Hospital, Khabarovsk, Russia.

Michael Maschan (M)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Alexey Maschan (A)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH